In recent years, the sales of several ADC drugs exceeding $1 billion after launch have attracted widespread market attention. The market enthusiasm for ADC drugs has driven a new wave of research in the overall conjugated drug market, including novel conjugated drugs such as RDC, PDC, and SMDC, which have gained market favor and rapidly increased capital attention. Based on unmet clinical needs, conjugated drugs that integrate multiple innovative modes have become a hot area in drug development.
Frost & Sullivan (Frost & Sullivan, abbreviated as "Frost & Sullivan") hereby releases the "Blue Book on the Current Situation and Development Trends of the Conjugated Drug Industry" (hereinafter referred to as the "Blue Book"), aiming to track the industry from multiple aspects such as technological development, marketed products, clinical pipelines, favorable policies, market growth, and capital enthusiasm, to demonstrate the development context of the industry, analyze the current industrial situation of the conjugated drug industry, and predict future development trends.
